Cutaneous melanoma: an update on therapies

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Lindholm C, Andersson R, Dufmats M et al. Invasive cutaneous malignant melanoma in Sweden, 1990–1999. A prospective, population-based study of survival and prognostic factors. Cancer 101, 2067–2078 (2004).
   PubMedGoogle Scholar
• Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the US? ‘Beware’ of the nodular subtype. Arch. Dermatol. 141, 745–750 (2005).
   PubMedGoogle Scholar
• Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch. Dermatol. 138, 609–614 (2002).
   PubMedGoogle Scholar
• Hersey P, Sillar RW, Howe CG et al. Factors related to the presentation of patients with thick primary melanomas. Med. J. Aust. 154, 583–587 (1991).
   PubMedGoogle Scholar
• Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust. Fam. Physician 32, 706–709 (2003).
   PubMedGoogle Scholar
• Abbasi NR, Shaw HM, Rigel DS et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292, 2771–2776 (2004).
   PubMed Web of Science ®Google Scholar
• Demierre MF, Sondak VK. Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit. Rev. Oncol. Hematol. 53, 225–239 (2005).
   PubMed Web of Science ®Google Scholar
• Demierre MF, Sondak VK. Chemoprevention of melanoma: theoretical and practical considerations. Cancer Control 12, 219–222 (2005).
   Google Scholar
• Gimotty PA, Guerry D, Ming ME et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. [erratum appears in J. Clin. Oncol. 23(3), 656 (2005)]. J. Clin. Oncol. 22, 3668–3676 (2004).
   Google Scholar
• Sondak VK, Taylor JMG, Sabel MS et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann. Surg. Oncol. 11, 247–258 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas JM, Newton-Bishop J, A’Hern R et al. Excision margins in high-risk malignant melanoma. N. Engl. J. Med. 350(8), 757–766 (2004).
   PubMed Web of Science ®Google Scholar
• Morton DL, Cochran AJ, Thompson JF et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann. Surg. 242, 302–313 (2005).
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J. Clin. Oncol. 17, 976–983 (1999).
   PubMed Web of Science ®Google Scholar
• Vuylsteke RJ, van Leeuwen PA, Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J. Clin. Onco. 21, 1057–1065 (2003).
   PubMed Web of Science ®Google Scholar
• Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am. J. Surg. Pathol. 29, 305–317 (2005).
   PubMed Web of Science ®Google Scholar
• Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J. Clin. Oncol. 22, 3989–3996 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson TM, Sondak VK, Bichakjian CK et al. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J. Am. Acad. Dermatol. 54(1), 19–27 (2006).
   PubMedGoogle Scholar
• Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635–3648 (2001).
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Ann. Surg. Oncol. 11, 362–374 (2004).
   PubMedGoogle Scholar
• Gershenwald JE, Berman RS, Porter G, Mansfield PF, Lee JE, Ross MI. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann. Surg. Oncol. 7, 226–231 (2000).
   PubMedGoogle Scholar
• Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. Low risk of in-transit metastasis in patients with cutaneous melanoma undergoing sentinal lymph node biopsy. J. Clin. Oncol. 23, 4588–4590 (2005).
   PubMedGoogle Scholar
• Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann. Surg. Oncol. 9, 637–645 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar R, Alavi A. Clinical applications of fluorodeoxyglucose-positron emission tomography in the management of malignant melanoma. Curr. Opin. Oncol. 17, 154–159 (2005).
   PubMedGoogle Scholar
• Wagner JD, Schauwecker D, Davidson D et al. Inefficacy of F-18 fluorodeoxy-δ-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 104, 570–579 (2005).
   PubMed Web of Science ®Google Scholar
• Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Impact of 2-deoxy-2[F-18] fluoro-δ-glucose positron emission tomography on the management of patients with advanced melanoma. Mol. Imaging Biol. (2006).
   Google Scholar
• Demierre MF, Koh HK. Adjuvant therapy for cutaneous malignant melanoma. J. Am. Acad. Dermatol. 36, 747–764 (1997).
   PubMedGoogle Scholar
• Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern co-operative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10, 1670–1677 (2004).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Richards T, Zarour HM et al. Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95, 1101–1112 (2002).
   PubMed Web of Science ®Google Scholar
• Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Co-ordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon α2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22, 53–61 (2004).
   PubMed Web of Science ®Google Scholar
• Kleeberg UR, Suciu S, Brocker EB et al. Final results of the EORTC 18871/DKG 80–1 randomised Phase III trial: rIFN-α2b versus rIFN-[γ] versus ISCADOR M(R) versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur. J. Cancer 40, 390–402 (2004).
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: time to Build upon the Foundation of High-dose Interferon α2b. J. Clin. Oncol. 22, 11–14 (2004).
   PubMedGoogle Scholar
• Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366, 1189–1196 (2005).
   PubMed Web of Science ®Google Scholar
• Demierre MF, Swetter S, Sondak V. Vaccine therapy of melanoma; an update. Curr. Cancer Therapy Rev. 1, 115–125 (2005).
   Google Scholar
• Chapman PB, Morrissey DM, Panageas KS et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin. Cancer Res. 6, 874–879 (2000).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim J, Lawson DH et al. High-dose interferon α-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Co-operative Oncology Group Phase II Trial E2696. J. Clin. Oncol. 19, 1430–1436 (2001).
   PubMed Web of Science ®Google Scholar
• Weber J. Melanoma peptide vaccines: from preclinical background to clinical trials. Curr. Oncol. Rep. 2, 38–47 (2000).
   PubMedGoogle Scholar
• Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T-cell responses: mechanisms and manipulation in tumor immunotherapy. Ann. Rev. Immunol. 19, 565–594 (2001).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T-lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Sanderson K, Scotland R, Lee P et al. Autoimmunity in a Phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23, 741–750 (2005).
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human Cancer. Nature 417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997–7000 (2002).
   Google Scholar
• Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357 (2005).
   PubMed Web of Science ®Google Scholar